- Home
- MAIA vs SACH Comparison
MAIA vs SACH Comparison
Compare MAIA & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- SACH
- Stock Information
- Founded
- MAIA 2018
- SACH 2010
- Country
- MAIA United States
- SACH United States
- Employees
- MAIA N/A
- SACH N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- SACH Real Estate Investment Trusts
- Sector
- MAIA Health Care
- SACH Real Estate
- Exchange
- MAIA Nasdaq
- SACH Nasdaq
- Market Cap
- MAIA 44.9M
- SACH 50.6M
- IPO Year
- MAIA 2022
- SACH 2017
- Fundamental
- Price
- MAIA $1.11
- SACH $1.06
- Analyst Decision
- MAIA
- SACH Hold
- Analyst Count
- MAIA 0
- SACH 4
- Target Price
- MAIA N/A
- SACH $2.00
- AVG Volume (30 Days)
- MAIA 742.2K
- SACH 138.0K
- Earning Date
- MAIA 11-07-2025
- SACH 11-05-2025
- Dividend Yield
- MAIA N/A
- SACH 18.87%
- EPS Growth
- MAIA N/A
- SACH N/A
- EPS
- MAIA N/A
- SACH N/A
- Revenue
- MAIA N/A
- SACH $4,046,000.00
- Revenue This Year
- MAIA N/A
- SACH N/A
- Revenue Next Year
- MAIA N/A
- SACH $6.63
- P/E Ratio
- MAIA N/A
- SACH N/A
- Revenue Growth
- MAIA N/A
- SACH N/A
- 52 Week Low
- MAIA $1.05
- SACH $0.80
- 52 Week High
- MAIA $3.48
- SACH $2.24
- Technical
- Relative Strength Index (RSI)
- MAIA 34.52
- SACH 40.74
- Support Level
- MAIA $1.05
- SACH $1.04
- Resistance Level
- MAIA $1.35
- SACH $1.10
- Average True Range (ATR)
- MAIA 0.10
- SACH 0.03
- MACD
- MAIA -0.03
- SACH 0.00
- Stochastic Oscillator
- MAIA 12.85
- SACH 14.50
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.